Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > GDF-15


Brief Information

Name:Growth/differentiation factor 15
Target Synonym:Placental TGF-beta,GDF-15,MIC1,PTGFB,MIC-1,PLAB,NSAID-activated gene 1 protein,Growth Differentiation Factor 15,Non-Steroidal Anti-Inflammatory Drug-Activated Gene-1,Placental Bone Morphogenetic Protein,NRG-1,PDF,Growth/Differentiation Factor 15,Macrophage Inhibitory Cytokine-1,PTGF-Beta,NSAID-regulated gene 1 protein,GDF15,Prostate Differentiation Factor,Macrophage Inhibitory Cytokine 1,NAG-1,NSAID (Nonsteroidal Anti-Inflammatory Drug)-Activated Protein 1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Phase 2 Clinical

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
GDF15 mAb - 01 PCC Metabolism Solid tumor,Cancer cachexia

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data


Immobilized Mouse GDF-15, His Tag (Cat. No. GD5-M5149) at 1 μg/mL (100 μL/well) can bind Human GFR alpha-like, Fc Tag (Cat. No. GFE-H5259) with a linear range of 0.3-10 ng/mL (QC tested).

GDF-15 MALS images

The purity of Biotinylated Human GDF-15, Avitag, Fc Tag (Cat. No. GD5-H82F9) is more than 85% and the molecular weight of this protein is around 80-95 kDa verified by SEC-MALS.

Synonym Name



Growth Differentiation Factor 15 (GDF-15), also called Macrophage Inhibitory Cytokine 1 (MIC-1). Expression of MIC-1 mRNA in monocytoid cells is up-regulated by a variety of stimuli associated with activation, including interleukin 1β, tumor necrosis factor α (TNF-α), interleukin 2, and macrophage colony-stimulating factor but not interferon γ, or lipopolysaccharide (LPS). It is highly expressed in cardiomyocytes, adipocytes, macrophages, endothelial cells, and vascular smooth muscle cells in normal and pathological condition. GDF-15 increases during tissue injury and inflammatory states and is associated with cardiometabolic risk. Increased GDF-15 levels are associated with cardiovascular diseases such as hypertrophy, heart failure, atherosclerosis, endothelial dysfunction, obesity, insulin resistance, diabetes, and chronic kidney diseases in diabetes. Increased GDF-15 level is linked with the progression and prognosis of the disease condition.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
NGM-120 NGM-120 Phase 2 Clinical Ngm Biopharmaceuticals Inc Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Anorexia; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Cachexia; Melanoma; Carcinoma, Non-Small-Cell Lung Details
CIN-109 CIN-109; JNJ-9090 Phase 1 Clinical Janssen Sciences Ireland Unlimited Company Obesity Details
NN-9215 Human-GDF15; MIC-1; NN-9215; LA-GDF15 Phase 1 Clinical Novo Nordisk A/S Obesity Details
Visugromab CTL-002 Phase 2 Clinical CatalYm GmbH Solid tumours; Urinary Bladder Neoplasms Details
Ponsegromab PF-06946860 Phase 2 Clinical Pfizer Inc Ovarian Neoplasms; Heart Failure; Fatigue; Pancreatic Neoplasms; Anorexia; Feeding and Eating Disorders; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Cachexia; Carcinoma, Non-Small-Cell Lung Details
AV-380 AV-380 Phase 1 Clinical Aveo Pharmaceuticals Inc Cachexia Details
GDF15 agonist (Lilly) Phase 1 Clinical Eli Lilly And Company Diabetes Mellitus Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message